Literature DB >> 16691004

Cloning, expression, and purification of lipoprotein-associated phospholipase A(2) in Pichia pastoris.

Fujun Zhang1, Yiping Wang.   

Abstract

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been shown to play a crucial role in atherosclerosis, and has been proposed as a promising target for drug discovery. Here, we cloned the Lp-PLA(2) gene from differentiated THP-1 cells, and inserted a carboxy-terminal His(6)-tagged version of the gene into the pPIC9 Pichia expression vector. The Lp-PLA(2) fusion protein was successfully expressed in Pichia pastoris expression system and could be rapidly purified to apparent homogeneity using a single-step purification method. The activity of our recombinant Lp-PLA(2) was strong when [3H] PAF was used as a substrate, and the Lp-PLA(2) inhibitor SB435495 exhibited an inhibitory curve against the recombinant Lp-PLA2 (IC50 = 15.93 +/- 1 microM). This novel recombinant Lp-PLA(2) could prove useful as a screening model for Lp-PLA(2) inhibitors, and may facilitate further investigation of this protein in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691004     DOI: 10.1385/MB:33:1:29

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  26 in total

Review 1.  Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.

Authors:  C H Macphee
Journal:  Curr Opin Pharmacol       Date:  2001-04       Impact factor: 5.547

Review 2.  Lipoprotein-associated phospholipase A2 as a target of therapy.

Authors:  Colin H Macphee; Jeanenne J Nelson; Andrew Zalewski
Journal:  Curr Opin Lipidol       Date:  2005-08       Impact factor: 4.776

Review 3.  Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.

Authors:  Colin Macphee; G Martin Benson; Yi Shi; Andrew Zalewski
Journal:  Expert Opin Investig Drugs       Date:  2005-06       Impact factor: 6.206

4.  1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).

Authors:  J C Bloomer; H F Boyd; D M Hickey; R J Ife; C A Leach; C H Macphee; K J Milliner; I L Pinto; D A Rawlings; S A Smith; I G Stansfield; S J Stanway; M A Taylor; C J Theobald; C M Whittaker
Journal:  Bioorg Med Chem Lett       Date:  2001-07-23       Impact factor: 2.823

5.  Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

Authors:  K L Carpenter; I F Dennis; I R Challis; D P Osborn; C H Macphee; D S Leake; M J Arends; M J Mitchinson
Journal:  FEBS Lett       Date:  2001-09-21       Impact factor: 4.124

6.  Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Authors:  Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-21       Impact factor: 8.311

Review 7.  Lp-PLA2: an emerging biomarker of coronary heart disease.

Authors:  Nisha Dada; Nam W Kim; Robert L Wolfert
Journal:  Expert Rev Mol Diagn       Date:  2002-01       Impact factor: 5.225

8.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

9.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

10.  The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Authors:  Josie A Blackie; Jackie C Bloomer; Murray J B Brown; Hung-Yuan Cheng; Richard L Elliott; Beverley Hammond; Deirdre M B Hickey; Robert J Ife; Colin A Leach; V Ann Lewis; Colin H Macphee; Kevin J Milliner; Kitty E Moores; Ivan L Pinto; Stephen A Smith; Ian G Stansfield; Steven J Stanway; Maxine A Taylor; Colin J Theobald; Caroline M Whittaker
Journal:  Bioorg Med Chem Lett       Date:  2002-09-16       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.